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The bioluminescence resonance energy transfer (BRET) technique has become extremely 
valuable for the real-time monitoring of protein–protein interactions in live cells. This method is 
highly amenable to the detection of G protein-coupled receptor (GPCR) interactions with proteins 
critical for regulating their function, such as β-arrestins. Of particular interest to endocrinologists 
is the ability to monitor interactions involving endocrine receptors, such as orexin receptor 2 or 
vasopressin type II receptor. The BRET method utilizes heterologous co-expression of fusion 
proteins linking one protein of interest (GPCR) to a bioluminescent donor enzyme, a variant of 
Renilla luciferase, and a second protein of interest (β-arrestin) to an acceptor fluorophore. If in 
close proximity, energy resulting from oxidation of the coelenterazine substrate by the donor will 
transfer to the acceptor, which in turn fluoresces. Using novel luciferase constructs, we were 
able to monitor interactions not detectable using less sensitive BRET combinations in the same 
configuration. In particular, we were able to show receptor/β-arrestin interactions in an agonist-
independent manner using Rluc8-tagged mutant receptors, in contrast to when using Rluc. 
Therefore, the enhanced BRET methodology has not only enabled live cell compound screening 
as we have recently published, it now provides a new level of sensitivity for monitoring specific 
transient, weak or hardly detectable protein–protein complexes, including agonist-independent 
GPCR/β-arrestin interactions. This has important implications for the use of BRET technologies 
in endocrine drug discovery programs as well as academic research.
Keywords: bioluminescence resonance energy transfer, luciferase, G protein-coupled receptor, arrestin, 
orexin, vasopressin
energy resulting from the rapid oxidation of a cell-permeable 
coelenterazine substrate by the luminophore will transfer to the 
fluorophore, which in turn fluoresces at a longer wavelength. 
BRET detection can be carried out using scanning spectrometry 
or dual-filter luminometry. Energy transfer implies that these mol-
ecules are in close proximity, and therefore, the proteins of inter-
est (e.g., GPCR and β-arrestin) fused to the donor and acceptor 
interact directly or as part of a complex (Pfleger and Eidne, 2006; 
Pfleger et al., 2006a,b; Kocan et al., 2008). There are currently two 
main BRET systems, BRET1 and BRET2. The BRET1 system uses 
the luciferase substrate coelenterazine h (benzyl-coelenterazine), 
with light emission peaking at ∼480 nm. Light emission from the 
corresponding acceptor is then observed at longer wavelengths 
following energy transfer (e.g., peaking at ∼510 nm for enhanced 
green fluorescent protein (EGFP) or ∼530 nm for yellow fluores-
cent proteins such as Venus). In contrast, the BRET2 system uses 
the luciferase substrate DeepBlueC (also known as coelenterazine 
400a, bisdeoxycoelenterazine, or di-dehydro coelenterazine), with 
consequent light emission peaking at about ∼400 nm. GFP10 or 
GFP2 is used as acceptor, with light emission peaking at ∼510 nm 
following energy transfer (Milligan and Bouvier, 2005; Pfleger and 
IntroductIon
Bioluminescence resonance energy transfer (BRET) is gaining 
increasing recognition as an advantageous approach for detecting 
protein–protein interactions in living cells and real time (Xu et al., 
2003; Pfleger and Eidne, 2006; Pfleger et al., 2006a; Kocan et al., 
2008). In particular, it has been utilized to investigate G protein-
coupled receptor (GPCR) interactions with both membrane and 
cytosolic proteins (Milligan, 2004; Milligan and Bouvier, 2005; 
Pfleger and Eidne, 2005; Pfleger et al., 2006a), including many 
critical for endocrine function. BRET is notably suitable for the 
detection of activation-dependent GPCR–protein interactions, 
especially involving scaffolding, regulatory and signaling proteins 
such as β-arrestins (Pfleger et al., 2006b; Kocan et al., 2008; Kocan 
and Pfleger, 2009).
The BRET method is based on heterologous co-expression of 
fusion proteins linking one protein of interest (e.g., GPCR) to a 
bioluminescent donor enzyme, a variant of Renilla luciferase (lumi-
nophore: Rluc, hRluc, Rluc2, or Rluc8), and a second protein of 
interest (e.g., β-arrestin) to an acceptor fluorophore, a variant of 
green fluorescent protein (Venus or GFP10). If the luminophore 
and fluorophore are less than 10 nm apart (Dacres et al., 2010), 
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V2R-R137L/Rluc8, and V2R-R137H/Rluc8 constructs have been 
described previously (Kocan et al., 2009). The V2R-wild type/
Rluc, V2R-R137C/Rluc, V2R-R137L/Rluc, and V2R-R137H/Rluc 
constructs were generated from the corresponding Rluc8-tagged 
constructs using the pcDNA3-TRHR/Rluc construct described 
previously (Kocan et al., 2008).
cell culture and transfectIon
HEK293FT and COS7 cells were maintained at 37°C, 5% CO
2
 in 
Complete Media (Dulbecco’s Modified Eagle’s Medium containing 
0.3 mg/ml glutamine, 100 IU/ml penicillin and 100 μg/ml strepto-
mycin; Gibco-BRL, Gaithersburg, MD, USA) supplemented with 
fetal calf serum (FCS; Gibco Life Technologies, Paisley, UK; 10% 
for HEK293FT and 5% for COS7 cells). Transient transfections 
were carried out 24 h after seeding using GeneJuice (Novagen) 
according to the manufacturer’s instructions.
MeasureMent of total InosItol phosphate productIon
Cells were split into 24-well plates 24 h following transient transfec-
tion, in inositol-free Complete Medium (MP Biomedicals, Irvine, 
CA, USA) containing 1% dialyzed FCS. The dose–response data 
were generated using COS7 cells and the comparison of lumino-
phores using HEK293FT cells. Six to eight hours later medium was 
replaced with inositol-free medium containing 1% dialyzed FCS 
and [3H]myo-inositol (Amersham Pharmacia Biotech, Uppsala, 
Sweden; 2 μCi/ml for dose–response curves and 1 μCi/ml for 
comparison of luminophores), followed by overnight incubation. 
Subsequently, cells were washed once with buffer A (1 mg/ml fatty 
acid-free BSA, 140 mM NaCl, 20 mM HEPES, 4 mM KCl, 8 mM 
d-glucose, 1 mM MgCl
2
 and 1 mM CaCl
2
), and again with buffer A 
plus 10 mM LiCl before incubating at 37°C for 50 min in buffer A 
containing 10 mM LiCl with or without agonist. After incubation, 
the assay buffer was removed and replaced with 10 mM formic 
acid for 1 h at 4°C. The acid was subsequently transferred to 5 ml 
tubes and the inositol phosphates bound to AG1-X8 anion-ex-
change resin (Bio-Rad Laboratories, Hercules, CA, USA). Following 
washes with water and 60 mM ammonium formate/5 mM sodium 
tetraborate, inositol phosphates were eluted with 1 M ammonium 
formate/0.1 M formic acid; 1 ml samples were mixed with 4 ml of 
Optiphase HiSafe 2 scintillant (Wallac, Turku, Finland) and radio-
activity measured using a 1209 Rackbeta liquid scintillation counter 
(Wallac). Total inositol phosphates were obtained by solubilizing 
cells in plates and inositol phosphate counts obtained from resin 
expressed relative to total inositol phosphate counts. All treatments 
were performed in triplicate.
spectral analysIs of luMInescent proteIns
HEK293FT cells were seeded in six-well plates at a density of 
630,000 cells per well and transfected with OxR2 cDNA (0.4 μg 
for all OxR2 constructs) and β-arrestin 2 cDNA (0.6 μg for all 
β-arrestin 2 constructs). Twenty-four hours after transfection, cells 
were harvested without trypsin in HEPES-buffered phenol red-
free complete medium containing 5% FCS and added to a poly-
l-lysine-coated white 96-well plate (Nunc, Rochester, NY, USA). 
Subsequently, the plate was incubated at 37°C, 5% CO
2
. At 48 h 
after transfection, medium in the plate was replaced with medium 
containing luciferase substrate: 5 μM coelenterazine h (for BRET1) 
Eidne, 2006; Pfleger et al., 2006a; Kocan et al., 2008, 2009; Kocan and 
Pfleger, 2009). The BRET1 system exhibits a higher BRET signal, in 
comparison to BRET2, allowing weaker interactions to be detected. 
Whereas the advantage of BRET2 is the increased separation of 
donor and acceptor emission spectra, which provides greater signal 
resolution. There is also recent experimental evidence to suggest 
that BRET2 has a greater Förster distance (distance at which the 
resonance energy transfer efficiency is half-maximal) than BRET1, 
these distances being determined as 4.4 and 7.5 nm respectively 
(Dacres et al., 2010).
We have recently demonstrated advances in the BRET tech-
nology enabling its application for live cell compound screening 
as exemplified using the thyrotropin-releasing hormone receptor 
(TRHR) interaction with β-arrestin (Kocan et al., 2008). These 
advances revolve around the use of novel luminophores Rluc2 and 
Rluc8 developed by the Gambhir laboratory (Loening et al., 2006), 
the latter of which is increasingly being adopted as the preferred 
luciferase for BRET (De et al., 2007, 2009; Guo et al., 2008; Kocan 
et al., 2008, 2009; Kamal et al., 2009; See et al., 2011). In the cur-
rent study, we have demonstrated how these novel luminophores 
have enabled detection of both agonist-induced GPCR/β-arrestin 
interactions utilizing orexin receptor 2 (OxR2), and agonist-
 independent GPCR/β-arrestin interactions using wild type vaso-
pressin type II receptor (V2R) and its clinically relevant mutants 
with gain-of-function (V2R-R137C and V2R-R137L) or loss-of-
function (V2R-R137H). Crucially, by comparing the use of different 
forms of luciferase fused to these vasopressin receptors, we show 
that the interactions observed using Rluc8 (Kocan et al., 2009) could 
not be detected using Rluc in the same configuration.
MaterIals and Methods
MaterIals
Orexin A (OxA) and Orexin B (OxB) were from the American 
Peptide Company (Sunnyvale, CA, USA) and arginine vaso-
pressin (AVP) was from Sigma-Aldrich (Castle Hill, Australia). 
The β-arrestin 2/Venus construct was prepared from pC2-Venus 
kindly provided by Atsushi Miyawaki (RIKEN Brain Science 
Institute, Wako-City, Japan). A PCR product for the Venus cod-
ing sequence was substituted in-frame into pcDNA3-β-arrestin 
2/Rluc replacing the Rluc cDNA as described previously (Kocan 
et al., 2008). The β-arrestin 2/GFP10 construct was prepared from 
the vector pcDNA3.1-GFP10 kindly provided by Michel Bouvier 
(Department of Biochemistry, University of Montreal, Canada). A 
PCR product for the GFP10 coding sequence was substituted in-
frame into pcDNA3-β-arrestin 2/Venus replacing the Venus cDNA 
as described previously (Kocan et al., 2008). Rluc8 cDNAs were 
amplified from the construct pcDNA3.1-Rluc8. This was kindly 
provided by Andreas Loening and Sanjiv Gambhir (Stanford 
University, Stanford, CA, USA; Loening et al., 2006). OxR2/Rluc 
was sub-cloned in a similar manner to the previously described 
OxR2/EGFP (Pfleger et al., 2006b), generated from a construct 
kindly provided by M. Yanagisawa (Howard Hughes Medical 
Institute, TX, USA). The EGFP tag was substituted in frame by 
the Rluc tag. PCR products for hRluc, Rluc2, or Rluc8 coding 
regions were substituted in-frame into pcDNA3-OxR2/Rluc 
replacing the Rluc cDNA to generate OxR2/hRluc, OxR2/Rluc2, 
and OxR2/Rluc8. The V2R-wild type/Rluc8, V2R-R137C/Rluc8, 
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(logM ± SEM) values upon OxA treatment were −8.6 ± 0.3 and 
−8.2 ± 0.6 for untagged and Rluc-tagged OxR2 respectively. Upon 
OxB treatment, these values were −8.6 ± 0.2 and −8.4 ± 0.1 respec-
tively. Moreover, no significant difference in inositol phosphate 
production was observed when comparing constructs with the dif-
ferent luminescent tags: Rluc, hRluc, Rluc2, and Rluc8 (Figure 2). 
Furthermore, the demonstration of a ligand-induced receptor/β-
arrestin interaction shown below provides additional confirmation 
of functionality. BRET-tagging of V2R constructs (wild type and 
the three mutants V2R-R137C, V2R-R137L, and V2R-R137H) was 
validated previously (Kocan et al., 2009).
coMparIson of luMInescence IntensItIes of orIgInal rluc-/
hrluc- and novel rluc2-/rluc8-tagged oxr2 constructs usIng 
scannIng spectroMetry
The emission spectra of four OxR2/luminophore fusion proteins 
were compared in order to demonstrate a difference in lumines-
cence intensity of original (Rluc and hRluc) versus novel (Rluc2 
and Rluc8) luminophores. Both BRET1 luciferase substrate coe-
lenterazine h (Figure 3A) as well as BRET2 luciferase substrate 
DeepBlueC (Figure 3B) were tested. The emission maximum 
or 10 μM DeepBlueC (for BRET2). Emission spectral scans were 
performed using a Cary Eclipse spectrophotometer (Varian, Palo 
Alto, CA, USA).
real-tIMe kInetIc Bret assays detectIng agonIst-Induced and 
agonIst-Independent gpcr–proteIn InteractIons In real tIMe 
and lIve cells
HEK293FT cells were seeded in six-well plates at a density of 630,000 
cells per well and transfected with OxR2 cDNA (0.4 μg for all OxR2 
constructs) and β-arrestin 2 cDNA (0.6 μg for all β-arrestin 2 con-
structs) or alternatively with V2R cDNA (0.1 μg for all V2R con-
structs) and β-arrestin 2 cDNA (0.3 μg for all β-arrestin 2 constructs). 
These cDNA amounts were established as the best cDNA ratio/
amounts for BRET following systematic comparison of different 
amounts. At 24 h after transfection, cells were harvested in HEPES-
buffered phenol red-free complete medium containing 5% FCS and 
added to a poly-l-lysine-coated white 96-well plate (Nunc) that was 
then incubated at 37°C, 5% CO
2
. Medium in the plate was replaced 
with PBS containing 5 μM coelenterazine h (for BRET1) or 10 μM 
DeepBlueC (for BRET2) and assays carried out immediately. BRET 
measurements were taken at 37°C using the VICTOR Light plate 
reader with Wallac 1420 software (PerkinElmer). Filtered light emis-
sions were sequentially measured through both the donor wavelength 
window (370–450 nm for luciferase with DeepBlueC or 400–475 nm 
for luciferase with coelenterazine h) and acceptor wavelength window 
(500–525 nm for GFP10 or 520–540 nm for Venus). For agonist-
induced interactions, the BRET signal was calculated by subtracting 
the ratio of emission through the acceptor wavelength window over 
emission through the donor wavelength window for a vehicle-treated 
cell sample from the same ratio for a second aliquot of the same cells 
treated with agonist, as described previously (Pfleger et al., 2006a,b; 
Kocan et al., 2008). Note that in this calculation, the vehicle-treated 
cell sample represents the background, eliminating the requirement 
for measuring a “donor-only” control sample (Pfleger et al., 2006a,b; 
Kocan et al., 2008). For agonist-independent interactions, the BRET 
ratio above wild type baseline was calculated as the ratio of emission 
through the acceptor wavelength window over emission through the 
donor wavelength window for each cell sample minus the same ratio 
for the vehicle-treated V2R-wild type cell sample. This calculation 
is similar to the ligand-induced BRET ratio described above, except 
that the background is determined using the vehicle-treated V2R-
wild type cell sample to observe agonist-independent BRET signals 
compared with V2R-wild type as described previously (Kocan et al., 
2009). The final pretreatment reading is presented at the zero time 
point (time of ligand or vehicle addition).
results
functIonal valIdatIon of gpcr/luMInophore fusIon proteIns
Bioluminescence resonance energy transfer constructs are prepared 
by fusing the protein of interest with the BRET tag (luminophore 
or fluorophore). Newly cloned fusion proteins need to be validated 
to ensure that addition of the tag does not impair their proper 
function (Pfleger et al., 2006b; Kocan et al., 2008). Total inosi-
tol phosphate assays, routinely used to evaluate ligand-induced 
Gq/11-mediated signaling, demonstrated that addition of Rluc to 
OxR2 did not alter the potency or efficacy of G protein-coupling 
following activation by either OxA or OxB (Figure 1). The logEC
50
 
FiGurE 1 | Functional validation of rluc-tagged Oxr2 compared with 
untagged Oxr2. Total inositol phosphate production was measured after 
addition of increasing concentrations of Orexin A (OxA) (A) or Orexin B (OxB) 
(B). Data shown are mean ± SEM of three independent experiments.
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as BRET2 substrate) revealed that Rluc8 always exhibited the highest 
intensity under the same conditions, followed by Rluc2. hRluc and 
Rluc always had significantly lower luminescence intensity irrespec-
tive of the coelenterazine analog employed. Using coelenterazine h, 
OxR2/Rluc8 maximal luminescence intensity was 1.8-fold higher in 
comparison to OxR2/Rluc2 however 3.5-fold higher in comparison 
to OxR2/hRluc and 6.4-fold higher when compared to OxR2/Rluc 
(Figure 3A). It was not possible to detect luminescence from oxi-
dation of DeepBlueC by Rluc and hRluc under these conditions. 
In contrast, the novel OxR2/Rluc2 and OxR2/Rluc8 constructs 
emitted detectable luminescence, with 2.2-fold higher intensity 
for OxR2/Rluc8 than for OxR2/Rluc2 (Figure 3B).
Comparison of luminophore-tagged fusion proteins in 
real-time kinetiC Bret1 and Bret2 assays deteCting agonist-
induCed interaCtions Between oxr2 and β-arrestin
We compared the performance of the original Rluc- and hRluc-
tagged OxR2 constructs with the novel Rluc2 and Rluc8-tagged 
OxR2 constructs in real-time kinetic BRET1 and BRET2 assays using 
luminometry. BRET signals were detected before and after addition 
of agonist (1 μM OxA) or vehicle (PBS) from cells co-transfected 
with different OxR2/luminophore and β-arrestin 2/fluorophore 
combinations using coelenterazine h (BRET1) or DeepBlueC 
(BRET2). Rluc2 and Rluc8 exhibited luminescence intensities 
(Figure 4) and BRET signals (Figure 5) that were always higher 
than Rluc or hRluc, regardless of the substrate used. For BRET1, 
significantly higher luminescence intensities were detected with 
Rluc2 and Rluc8-tagged OxR2 constructs whereas luminescence 
intensities of hRluc and Rluc were reaching the limits of detection 
within an hour (Figure 4A). With regards to BRET2, with a stand-
ard luminometer it was not possible to detect a BRET2 signal for 
more than a few seconds with the originally used luminophores 
Rluc and hRluc due to the low luminescence intensity resulting 
using  coelenterazine h was detected at ∼480 nm for all constructs 
(Figure 3A). In contrast, the emission maxima could not be estab-
lished for DeepBlueC using Rluc or hRluc, but a peak for both Rluc2 
and Rluc8 was observed at ∼420 nm (Figure 3B). The comparison 
of luminescence intensities of different luciferase mutants with coe-
lenterazine h (used as BRET1 substrate) as well as DeepBlueC (used 
FigurE 2 | Functional validation of different luciferase-tagged Oxr2 
BrET fusion proteins. Total inositol phosphate production was measured 
after addition of vehicle or OxA in HEK293FT cells transfected with one of 
various OxR2/luminophore constructs. Data shown are mean ± SEM of three 
independent experiments each carried out in triplicate. Data generated with 
OxA-treated cells were analyzed by one-way ANOVA and differences between 
cells transfected with the various OxR2/luminophore constructs were not 
significant (P > 0.05).
FigurE 3 | Spectral analysis comparing luminescence intensities of 
different luciferase-tagged Oxr2 fusion proteins using coelenterazine 
h or DeepBlueC as luciferase substrate. HEK293FT cells were 
co-transfected with β-arrestin 2/Venus (A) or β-arrestin 2/GFP10 (B) and OxR2 
tagged with various luciferase constructs. Emission spectra were recorded 
immediately after addition of coelenterazine h (A) or DeepBlueC (B). For the 
BRET1 system (A), the emission maximum of ∼480 nm corresponds to the 
luciferase oxidizing its substrate coelenterazine h. For the BRET2 system (B), 
the emission maximum of ∼420 nm corresponds to the luciferase oxidizing its 
substrate DeepBlueC.
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and mutant V2Rs (V2R-R137C, V2R-R137L, and V2R-R137H) 
with β-arrestin 2 were measured before and after stimulation of 
the cells with three different concentrations of agonist AVP (final 
concentrations 1, 0.1, and 0.01 μM) or vehicle (PBS). Firstly, com-
paring agonist-induced V2R/β-arrestin interactions with wild 
type V2R tagged with novel Rluc8 versus original Rluc, a sub-
stantially improved BRET signal was observed using the Rluc8 
tag, allowing a concentration-dependent response to be clearly 
detected (Figures 6A,B). Subsequently, comparing V2R-R137C/
Rluc8, V2R-R137L/Rluc8, and V2R-R137H/Rluc8 to V2R-wild 
type/Rluc8, all three mutants showed elevated BRET signals for 
untreated cells, indicating agonist-independent interactions of all 
of the V2R mutants with β-arrestin 2 (Figures 6A,C,E,G). In con-
trast, it was not possible to detect agonist-independent β-arrestin 
interactions with any of the three V2R mutants tagged with Rluc 
(Figures 6D,F,H).
The relative luminescence of the Rluc8- or Rluc-tagged V2R 
mutants compared with the corresponding luminophore-tagged 
wild type V2R is presented in Table 1. Note that the Rluc8-tagged 
mutant receptors express at similar or slightly lower levels to the 
corresponding wild type receptor. Consequently, the findings 
from DeepBlueC oxidation. In contrast, the novel Rluc2 and Rluc8 
exhibited greater and more sustained luminescence signals lasting 
over 1 h following DeepBlueC addition (Figure 4B). These differ-
ences in luminescence were reflected in the greater BRET signals 
with Rluc2 and Rluc8 fusion proteins in contrast to hRluc and Rluc 
under the same conditions (Figure 5). Indeed, in the case of BRET2 
(with DeepBlueC as luminophore substrate), it was now possible 
to detect a kinetic BRET signal monitoring the ligand-induced 
OxR2/β-arrestin interaction with Rluc2 and Rluc8 in contrast to 
Rluc and hRluc (Figure 5B).
detectIon of agonIst-Independent InteractIons of v2r 
Mutants wIth β-arrestIns In real-tIMe kInetIc Bret assays 
usIng dual-fIlter luMInoMetry
In order to demonstrate the ability of Rluc8 to enable monitoring 
of agonist-independent protein–protein interactions compared 
to Rluc, V2R mutants exhibiting agonist-independent β-arrestin 
recruitment were employed (Kocan et al., 2009; Tenenbaum et al., 
2009; Rochdi et al., 2010). BRET signals were detected from cells 
co-transfected with different V2R/Rluc8 or V2R/Rluc constructs 
and β-arrestin/Venus fusion proteins. Interactions of the wild type 
FiGurE 4 | Comparison of luminescence intensities of different luciferase-
tagged Oxr2 fusion proteins over time oxidizing different luciferase 
substrates: coelenterazine h and DeepBlueC. HEK293FT cells were 
transiently co-transfected with OxR2 tagged with various luciferase constructs 
and β-arrestin 2/Venus (A) or β-arrestin 2/GFP10 (B). Luciferase substrates were 
added immediately prior to real-time measurement at 37°C. Cells were assayed 
before and after treatment with vehicle (data for which are shown in this figure) 
or OxA (data not shown). These data were collected as part of the BRET assay 
and were also used for calculation of the corresponding BRET ratio presented in 
Figure 5. Results shown are representative of three independent experiments.
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dIscussIon
We have demonstrated clear improvements in our ability to detect 
agonist-induced β-arrestin interactions with the endocrine recep-
tors OxR2 and V2R.
The orexin neuropeptide receptors 1 and 2 (OxR1 and OxR2) 
have been implicated in diverse physiological and pathological 
roles, including sleep/wake regulation, reward/addiction, and 
energy homeostasis (Tsujino and Sakurai, 2009). Using BRET1 
and extended BRET (eBRET), we have previously demonstrated 
monitoring of OxR2 recruitment of β-arrestin using Rluc-tagged 
β-arrestin 1 and OxR2/EGFP (Pfleger et al., 2006b, 2007). Using 
the BRET2 methodology with Rluc or hRluc luminophores, it was 
not possible to detect OxR2/β-arrestin interactions. By employing 
the novel Rluc2 and Rluc8 BRET constructs, we have now been 
able to detect OxR2/β-arrestin interactions with the BRET2 sys-
tem over prolonged periods with a very stable signal. Substantial 
improvements to the ability of the BRET1 system to monitor the 
same interaction were also observed. These results are in agreement 
with our previous data investigating TRHR/β-arrestin interactions 
(Kocan et al., 2008).
Vasopressin type II receptor is activated by AVP and regulates 
normal fluid homeostasis in the body by mediating excretion of 
free water. V2R mutants of arginine 137 in the DRY/H motif have 
significant clinical relevance, exhibiting diverse disease phenotypes. 
Gain-of-function mutants V2R-R137C and V2R-R137L cause 
nephrogenic syndrome of inappropriate antidiuresis (NSIAD), 
a genetic disease where the body is unable to excrete free water. 
Despite undetectable AVP levels, patients have inappropriately 
concentrated urine resulting in hyponatremia, hypo-osmolality, 
and natriuresis (Feldman et al., 2005). In contrast, mutation at 
the identical position, but changing arginine to histidine (V2R-
R137H), causes nephrogenic diabetes insipidus (NDI), a genetic 
disease associated with a loss of the kidney’s ability to concentrate 
urine. V2R-R137H is a loss-of-function mutant exhibiting impaired 
trafficking, impaired signaling, and constitutive internalization 
(Barak et al., 2001; Bernier et al., 2004).
Our recent study was the first to show that the gain-of-function 
mutants V2R-R137C and V2R-R137L, in addition to constitutive 
signaling, exhibit agonist-independent β-arrestin interactions and 
internalization (Kocan et al., 2009). These findings have since been 
confirmed by other laboratories (Tenenbaum et al., 2009; Rochdi 
et al., 2010). Interestingly, the elegant study by Tenenbaum et al. 
(2009) observed agonist-independent interactions between the 
mutant V2Rs using YFP-tagged V2R constructs and Rluc-tagged 
β-arrestin 1 in COS-7 cells, but not Rluc-tagged V2R constructs 
and β-arrestin 1-YFP (the reverse configuration). Similar results 
were obtained with β-arrestin 2 and in HEK293 cells (Tenenbaum 
et al., 2009). This discrepancy of findings between the two BRET 
configurations was suggested to be due to differences in the dis-
tance or orientation of the donor and acceptor, which is indeed 
likely to be the case. However, the question remained as to why 
we were able to show agonist-independent β-arrestin interac-
tions with the mutant V2Rs using Rluc8-tagged V2R constructs 
(Kocan et al., 2009), in contrast to the findings of Tenenbaum et al. 
(2009) using Rluc-tagged V2R constructs. As we had previously 
produced similar findings with both BRET1 and BRET2 using Venus 
and GFP10 as acceptor respectively (Kocan et al., 2009), we did 
from the BRET assays with Rluc8 are not due to increased expres-
sion levels of the mutant receptors compared with the wild type 
V2R. Furthermore, Rluc-tagged V2R mutants were expressed 
at similar or slightly higher levels than the corresponding wild 
type V2R. Thus, the lack of agonist-independent BRET signal 
with Rluc for V2R mutants is not due to decreased expression 
levels of the mutant receptors compared with the wild type 
receptor (Table 1).
FiGurE 5 | Detection of protein–protein interactions by real time BrET1 
and BrET2 assays. Kinetic data comparing the BRET performance of different 
receptor/luminophore fusion proteins using the OxA-induced interaction 
between OxR2/luminophore and β-arrestin 2/Venus for BRET1 (A) or β-arrestin 
2/GFP10 for BRET2 (B). Transiently co-transfected HEK293FT cells were 
assayed before and after treatment with OxA or vehicle. Luciferase substrates 
coelenterazine h for BRET1 (A) or DeepBlueC for BRET2 (B) were added 
immediately prior to real-time measurements at 37°C. The ligand-induced 
BRET ratios are calculated as described in Section “Materials and Methods.” 
Data shown are mean ± SEM of three independent experiments.
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FiGurE 6 | Detection of protein–protein interactions by real-time BrET1 
assay. Kinetic data comparing V2R-wild type (A,B) and the three different 
mutants V2R-R137C (C,D), V2R-R137L (E,F), and V2R-R137H (G,H) tagged 
with Rluc8 (A,C,E,G) or Rluc (B,D,F,H) were generated by monitoring the 
interaction with β-arrestin 2/Venus. The luciferase substrate coelenterazine 
h was added immediately before real-time measurements at 37°C. The 
transiently co-transfected HEK293FT cells were assayed before and after 
treatment with AVP (final concentrations of 1, 0.1, and 0.01 μM) or 
vehicle. BRET ratio above wild type baseline was calculated as described in 
Section “Materials and Methods.” Data shown are mean ± SEM of four 
independent experiments. Parts of this figure (A,C,E,G) have been 
adapted from that published previously (Kocan et al., 2009) and are included 
for comparison with permission from the journal. Copyright 2009, The 
Endocrine Society.
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Table 1 | relative luminescence intensities of the three V2r mutants 
investigated compared with the luminescence intensity of the 
corresponding V2r-wild type construct (V2r-wild type/rluc8 or 
V2r-wild type/rluc).
Transfected luminophore Luminescence relative to 
construct corresponding V2r-wild  
 type/luminophore (%)
V2R-R137C/Rluc8 84.9 ± 3.1
V2R-R137L/Rluc8 101.0 ± 4.1
V2R-R137H/Rluc8 77.7 ± 3.4
V2R-R137C/Rluc 129.2 ± 8.8
V2R-R137L/Rluc 127.2 ± 11.1
V2R-R137H/Rluc 100.3 ± 8.7
Luminescence intensities were detected as part of the BRET kinetic assay, with 
the cells being co-transfected with β-arrestin 2/Venus.
Data shown are mean ± SEM of four independent experiments.
Data for Rluc8-tagged constructs have been published previously (Kocan et al., 
2009) and are included for comparison.
not expect the choice of acceptor fluorophore to be the reason. 
Therefore, in the current study we have addressed the question 
by comparing the ability of the Rluc and Rluc8 luminophores to 
detect these agonist-independent interactions under the same 
experimental conditions.
We have found that, in contrast to mutant Rluc8-tagged V2Rs, 
mutant Rluc-tagged V2Rs did not generate agonist-independent 
BRET signals above wild type baseline indicative of constitutive 
interactions with β-arrestin 2/Venus. These findings are therefore 
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